CDA | Evidence Driven
CDA | Evidence Driven

Yervoy for First Line Advanced Melanoma - Details

Détails

Fichiers
Generic Name:
Ipilimumab
État du projet:
Terminé
Domaine thérapeutique:
First Line Advanced Melanoma
Fabricant:
Bristol-Myers Squibb Canada
Brand Name:
Yervoy
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0042-000
Indicateur de rendement:
S. O. – Mesures de rendement prédictives
Strength:
5mg/mL
Tumour Type:
Peau et mélanome
Indications:
First Line Advanced Melanoma
Funding Request:
For the first-line treatment of adult patients with advanced (unresectable or metastatic) melanoma
Review Status:
Complete
Pre Noc Submission:
Yes
Date NOC Issued:
Sponsor:
Bristol-Myers Squibb Canada
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Non demandée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Remboursement sous critères cliniques ou conditions
pERC Meeting:
Final Recommendation Issued:

Fichiers

Provincial Funding Summary Résumé, financement provincial Afficher le PDF
Ipilimumab (Yervoy) First Line Advanced Melanoma - pERC Final Recommendation Recommandation finale 22 décembre 2014 Afficher le PDF
Ipilimumab (Yervoy) First Line Advanced Melanoma - Final Clinical Guidance Report Rapports d'orientation 22 décembre 2014 Afficher le PDF
Ipilimumab (Yervoy) First Line Advanced Melanoma - Final Economic Guidance Report Rapports d'orientation 22 décembre 2014 Afficher le PDF
Ipilimumab (Yervoy) First Line Advanced Melanoma - pERC Initial Recommendation Recommandation initiale 04 décembre 2014 Afficher le PDF
Ipilimumab (Yervoy) First Line Advanced Melanoma - PAG Feedback on Initial Recommendation Rétroaction 22 décembre 2014 Afficher le PDF
Ipilimumab (Yervoy) First Line Advanced Melanoma - Manufacturer (Bristol-Myers Squibb Canada) Feedback on Initial Recommendation Rétroaction 22 décembre 2014 Afficher le PDF
Ipilimumab (Yervoy) First Line Advanced Melanoma - Patient Advocacy Group (MNC) Feedback on Initial Recommendation Rétroaction 22 décembre 2014 Afficher le PDF
Ipilimumab (Yervoy) First Line Advanced Melanoma - Patient Advocacy Group (MNC) COI Declarations Rétroaction 22 décembre 2014 Afficher le PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Dernière mise à jour : 02 septembre 2016